SAN FRANCISCO, November 16, 2016 /PRNewswire/ --
The U.S. IVD for autoimmune diseases market was valued at USD 4.0 billion in 2015 and is expected to reach a value of USD 4.74 billion by 2024 .The U.S. Laboratory Developed Test (LDT) for autoimmune diseases was valued at USD 830.9 million in 2015. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.
(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )
These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.
A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.
It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.
The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.
Browse full research report with TOC on "U.S. In Vitro Diagnostics (IVD) And Laboratory Developed Tests (LDT) For Autoimmune Diseases Market (Ankylosing Spondylitis (AS), Alopecia Areata, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Psoriasis) By Technology, Report, 2013 - 2024" at: http://www.grandviewresearch.com/industry-analysis/us-in-vitro-diagnostics-ivd-laboratory-developed-tests-ldt-autoimmune-diseases-market
Further Key Findings from the Study Suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the U.S. IVD and LDT for autoimmune diseases market by application and technology:
Access research insight: http://www.grandviewresearch.com/research-insights/us-ivd-ldt-autoimmune-diseases-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Read Our Blogs - grandviewresearch.com/blogs/healthcare
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Share this article